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Non-Pseudomonas Gram-negative (NPGN) peritonitis is a
frequent, serious complication of peritoneal dialysis;
however, previous reports have been limited to small, single-
center studies. To gain insight on the frequency, predictors,
treatment, and outcomes of NPGN peritonitis, we analyzed
data in the ANZDATA registry of all adult Australian
peritoneal dialysis patients over a 39-month period using
multivariate logistic and multilevel Poisson regressions. There
were 837 episodes of NPGN peritonitis (23.3% of all
peritonitis) that occurred in 256 patients. The most common
organism isolated was Escherichia coli, but included Klebsiella,
Enterobacter, Serratia, Acinetobacter, Proteus, and Citrobacter,
with multiple organisms identified in a quarter of the
patients. The principal risk factor was older age, with poorer
clinical outcome predicted by older age and polymicrobial
peritonitis. The overall antibiotic cure rate was 59%. NPGN
peritonitis was associated with significantly higher risks of
hospitalization, catheter removal, permanent transfer to
hemodialysis, and death compared to other organisms
contributing to peritonitis. Underlying bowel perforation
requiring surgery was uncommon. Hence, we show that
NPGN peritonitis is a frequent, serious complication of
peritoneal dialysis, which is frequently associated with
significant risks, including death. Its cure with antibiotics
alone is less likely when multiple organisms are involved.
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Peritonitis is a serious complication of peritoneal dialysis
(PD), accounting for 30% of technique failures and 21% of
infectious deaths in Australian and New Zealand PD patients.1
The overall rates of peritonitis have decreased since the early
1990s1–3 because of advances in connectology and Staphylococcus
decolonization protocols.2,4–6 These improvements have primarily
made an impact on the incidence of Gram-positive perito-
nitis, in such a manner that the proportion of PD-associated
infections due to Gram-negative organisms has consequently
increased.2–4 Available data suggest that non-Pseudomonas
Gram-negative (NPGN) organisms now account for approxi-
mately 20–30% of all peritonitis episodes, are often more
severe than other forms of PD-associated peritonitis, and are
associated with worse clinical outcomes, including catheter
loss, technique failure, and death.2,3,7–9
The 2005 update of the International Society of PD
(ISPD) Guidelines for Management of PD-related Infections
recommends treatment of NPGN peritonitis with an
appropriate single antimicrobial agent (for example, amino-
glycoside, ceftazidime, cefepime, carbapenem, or quinolone),
based on in vitro antibiotic sensitivity testing, for a period of
3 weeks.9 However, these recommendations are based on
limited earlier data from small, retrospective, often single-
center observational cohort studies.7,10 There has not
been a comprehensive examination of different therapeutic
approaches to NPGN peritonitis across multiple centers.
Moreover, a more recent, single-center study from Hong
Kong suggested that single-agent antibiotic therapy was
associated with an increased risk of Enterobacteriaceae
peritonitis relapse compared with dual antibiotic therapy.3
The aim of the current study was to examine the frequency,
predictors, treatment, and clinical outcomes of NPGN peritonitis
in all Australian PD patients involving 66 PD centers.
RESULTS
Population characteristics
A total of 4675 patients received PD in Australia during
the study period (1 October 2003 to 31 December 2006).
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They were followed up for 6002 patient-years. Eight hundred
and thirty-seven episodes of NPGN peritonitis occurred in
256 individuals. NPGN species accounted for 23.3% of all the
3594 peritonitis episodes. The rate of NPGN peritonitis was
0.14 episodes per patient-year of treatment. The causes of
single-organism NPGN peritonitis (n¼ 626) were Acineto-
bacter (n¼ 45), E. coli (n¼ 206), Klebsiella (n¼ 128), Entero-
bacter (n¼ 74), Serratia (n¼ 69), Proteus (n¼ 23),
Citrobacter (n¼ 14), other Enterobacteriaceae (n¼ 2), Neis-
seria (n¼ 9), and other Gram-negative organisms (n¼ 56).
Multiple organisms were isolated in 211 (25%) episodes of
NPGN peritonitis, including coagulase-negative staphylo-
cocci (n¼ 24), Staphylococcus aureus (n¼ 13), Enterococci
(n¼ 29), other Gram-positive organisms (n¼ 7), Pseudo-
monas (n¼ 26), Acinetobacter (n¼ 21), E. coli (n¼ 79),
Klebsiella (n¼ 61), Enterobacter (n¼ 39), Serratia (n¼ 10),
Proteus (n¼ 18), Citrobacter (n¼ 12), other Enterobacteria-
ceae (n¼ 12), Neisseria (n¼ 5), other Gram-negative organ-
isms (n¼ 33), anaerobic bacteria (n¼ 4), fungi (n¼ 22), and
other organisms (n¼ 21). One hundred and seventy-four
episodes of peritonitis were associated with 2 organisms, and
37 episodes were associated with 3 organisms. Five hundred
and twenty-eight patients experienced 1 episode of NPGN
peritonitis during the study period, 90 experienced 2 episodes,
27 experienced 3 episodes, 7 experienced 4 episodes, 2 experienced
5 episodes, and 1 experienced 6 episodes.
Underlying bowel perforations due to diverticular disease,
bowel infarction, hernia incarceration, or appendicitis were
reported in a small proportion of patients, but were
significantly more common in NPGN peritonitis episodes
than in other peritonitis episodes (9 or 1.1% vs 3 or 0.1%,
Po0.001, odds ratio (OR) 10.0, 95% confidence interval (CI)
2.70–36.9). Bowel perforation was significantly more com-
mon in polymicrobial than in single-organism NPGN
peritonitis (5 or 2.4% vs 4 or 0.6%, Po0.05, OR 3.77, 95%
CI 1.004–14.2).
Predictors of NPGN peritonitis
The characteristics of patients who did and who did not
experience NPGN peritonitis are shown in Table 1. On
univariate analysis, patients who experienced NPGN perito-
nitis during the study period were more likely to be older, of
Aboriginal and Torres Strait Islander racial origin, Maori and
Pacific Islander racial origin, Asian racial origin, non-
diabetic, and to have a baseline PET showing a higher
peritoneal transport status or living in New South Wales.
Using multivariate, multilevel mixed-effects Poisson regres-
sion analysis, the occurrence of NPGN peritonitis was
significantly and independently predicted by older age
(youngest tertile reference; middle tertile adjusted OR 1.15,
95% CI 0.92–1.44; oldest tertile OR 1.68, 95% CI 1.34–2.11)
and ESRF due to diabetic nephropathy (OR 0.66, 95% CI
0.52–0.83). There was a trend to increased occurrence of
NPGN peritonitis in females (OR 1.16, 95% CI 0.98–1.38),
but this did not achieve statistical significance (P¼ 0.08). The
development of NPGN peritonitis was not associated with
racial origin, BMI, kidney function at dialysis commencement,
current smoking status, coronary artery disease, chronic lung
disease, cerebrovascular disease, peripheral vascular disease,
peritoneal transport status, or late referral within 3 months of
needing to start dialysis. The findings were unchanged when
only single-organism peritonitis episodes were considered.
Effect of previous peritonitis episodes on occurrence of NPGN
peritonitis
A history of previous peritonitis was significantly more
common for NPGN than for other peritonitis episodes (89 vs
31%, Po0.001). The time elapsed between an earlier
peritonitis episode and the subsequent one was not
significantly different between NPGN peritonitis (median
period 77 days, interquartile range (IQR) 37–185 days) and
other forms of peritonitis (median period 80 days, IQR
29.25–172.25 days, P¼ 0.3). Consequently, the probability of
an episode of subsequent peritonitis being caused by an
NPGN species as opposed to another organism remained
constant over time (21% in the first 60 days, 22% in the first
year, 22% after the first year, P¼ 1.0).
Treatment of NPGN peritonitis
The vast majority of patients with NPGN peritonitis were
initially treated with either intraperitoneal vancomycin or
cephazolin in combination with gentamicin as empirical
therapy (Table 2). Once culture results became known at a
median time of 3 days, approximately two-thirds of the
patients were changed to a second antibiotic regimen, the
most common of which were gentamicin monotherapy
(14%), ciprofloxacin monotherapy (10%), and ceftriaxone
monotherapy (5%). Of those peritonitis episodes in which a
second antibiotic regimen was used, 382 (71%) involved
treatment with a single antimicrobial agent, 136 (25%)
involved two agents, and 21 (4%) involved three agents.
Patients were changed to a third antibiotic regimen in 21% of
the episodes after a median period of 7 days. Overall, the
median total antibiotic course duration was 14 days, which
was slightly but significantly longer than for all the other
organisms (Table 3). Heparin was administered to the
dialysate in 178 (21%) episodes of NPGN peritonitis.
Streptokinase was instilled in the PD catheter in 5 (1%)
episodes of NPGN peritonitis and only 59 (7%) patients with
NPGN peritonitis received concomitant prophylactic nystatin
therapy.
Outcomes of NPGN peritonitis
The overall cure rate for NPGN peritonitis was 59%.
Compared with other organisms, NPGN peritonitis was
associated with significantly lower risks of relapse (11 vs
15%), but higher risks of hospitalization (81 vs 66%),
catheter removal (31 vs 19%), permanent hemodialysis
transfer (26 vs 15%), and death (4 vs 2%) (Table 3). NPGN
peritonitis was also associated with a longer duration of
hospitalization (Table 3). No cases of encapsulating perito-
neal sclerosis (EPS) after NPGN peritonitis were reported.
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The outcomes of peritonitis due to NPGN organisms vs
other organisms were similar when single-organism and
polymicrobial peritonitis episodes were separately considered
(Table 4). Compared with single-organism peritonitis,
polymicrobial episodes were associated with greater fre-
quency of changes to second and third antimicrobial
regimens and increased occurrences of hospitalization,
catheter removal, permanent hemodialysis transfer, and
death (Table 4).
The administration of vancomycin, cephalosporin, or any
other agent in the initial or subsequent empirical antibiotic
regimens did not significantly influence NPGN peritonitis
outcomes on either univariate or multivariate analyses.
Similarly, the Gram-negative cover used (aminoglycoside or
any other agent) did not significantly influence the NPGN
peritonitis outcomes. When catheter removal was required to
treat NPGN peritonitis, removal of the catheter within the
first 5 days of peritonitis onset as opposed to later did not
significantly affect the probabilities of either permanent
hemodialysis transfer (83 vs 83%, respectively, P¼ 0.9) or
death (4.5 vs 5.7%, P¼ 0.9). Similar results were obtained
when only episodes of single NPGN organism peritonitis
were considered (permanent hemodialysis transfer 83 vs
81%, P¼ 0.9; death 4.6 vs 4.7%, P¼ 0.7).
On using multivariable, multilevel mixed-effects logistic
regression, isolation of multiple organisms in NPGN
peritonitis was associated with increased risks of catheter
removal (OR 3.28, 95% CI 2.17–4.96) and permanent
Table 1 | Characteristics of all Australian PD patients who did
and who did not experience non-Pseudomonas Gram-negative
peritonitis at any stage during the period 2003–2006
Characteristic
Non-
Pseudomonas
Gram-negative
peritonitis
(n=655)
No non-
Pseudomonas
Gram-negative
peritonitis
(n=4020) P value
Age (years) 64.1±15.9 61.1±16.8 o0.001
Women 338 (52%) 2211 (55%) 0.11
Racial origin 0.049
Caucasian 476 (73%) 3105 (77%)
Aboriginal/Torres
Strait Islander
58 (9%) 303 (8%)
Maori/Pacific
Islander
17 (3%) 90 (2%)
Asian 80 (12%) 361 (9%)
Other 24 (4%) 161 (4%)
BMI (kg/m2) 25.7±5.3 25.9±6.5 0.4
eGFR at dialysis start
(ml/min per 1.73m2)
7.0±5.5 7.1±4.3 0.5
Late referral 156 (24%) 955 (24%) 0.8
ESRF cause 0.3
Chronic
glomerulonephritis
192 (29%) 1131 (28%)
Diabetic nephropathy 160 (24%) 1159 (29%)
Renovascular disease 96 (15%) 543 (14%)
Polycystic kidneys 45 (7%) 211 (5%)
Reflux nephropathy 27 (4%) 170 (4%)
Other 90 (14%) 555 (14%)
Unknown 45 (7%) 251 (6%)
Current smoker 75 (11%) 482 (12%) 0.7
Chronic lung disease 81 (12%) 518 (13%) 0.7
Coronary artery disease 247 (38%) 1420 (35%) 0.2
Peripheral vascular disease 131 (20%) 915 (23%) 0.12
Cerebrovascular disease 73 (11%) 535 (13%) 0.13
Diabetes mellitus 219 (33%) 1519 (38%) 0.03
Peritoneal transport status o0.001
High 81 (12%) 390 (10%)
High average 248 (38%) 1463 (36%)
Low average 169 (26%) 909 (23%)
Low 30 (5%) 168 (4%)
Unknown/not specified 127 (19%) 1090 (27%)
Centre size (no. of PD patients) 0.3
Small (p10) 4 (1%) 51 (1%)
Small–medium (11–38) 43 (7%) 278 (7%)
Medium–large (39–98) 135 (21%) 893 (22%)
Large (X99) 473 (72%) 2798 (70%)
State 0.001
New South Wales 291 (44%) 1541 (38%)
Northern Territory 18 (3%) 67 (2%)
Queensland 110 (17%) 845 (21%)
South Australia 30 (3%) 265 (7%)
Tasmania 7 (1%) 70 (2%)
Victoria 121 (18%) 839 (21%)
Western Australia 78 (12%) 393 (10%)
Abbreviation: PD, peritoneal dialysis.
Table 2 | Antimicrobial agents prescribed in the initial,
second, and third antibiotic regimens for NPGN peritonitis
episodes in Australian PD patients, 2003–2006
Antibiotic
First regimen
(n=837)
Second regimen
(n=539)
Third regimen
(n=173)
Cephazolin 332 (40%) 59 (11%) 9 (5%)
Vancomycin 355 (42%) 76 (14%) 16 (9%)
Gentamicin 649 (78%) 229 (42%) 40 (23%)
Amikacin 3 (0.4%) 3 (1%) 1 (1%)
Tobramycin 0 (0%) 0 (0%) 1 (1%)
Ceftazidime 76 (9%) 12 (2%) 2 (1%)
Cefoxitin 15 (2%) 6 (1%) 2 (1%)
Cefipime 7 (1%) 1 (0.2%) 0 (0%)
Cephalothin 63 (8%) 18 (3%) 3 (2%)
Ceftriaxone 20 (2%) 53 (10%) 13 (8%)
Cefotaxime 6 (1%) 17 (3%) 4 (2%)
Cephalexin 25 (3%) 22 (4%) 11 (6%)
Other cephalosporin 2 (0.2%) 0 (0%) 0 (0%)
Ampicillin 3 (0.4%) 8 (1%) 3 (2%)
Amoxycillin 4 (0.5%) 12 (2%) 10 (6%)
Amoxycillin+clavulanate 21 (3%) 12 (2%) 9 (5%)
Dicloxacillin/Flucloxacillin 4 (0.5%) 3 (1%) 2 (1%)
Other penicillin 2 (1%) 2 (1%) 0 (0%)
Ciprofloxacin 55 (7%) 98 (18%) 65 (38%)
Metronidazole 11 (2%) 28 (5%) 16 (9%)
Cotrimoxazole 0 (0%) 4 (1%) 6 (3%)
Erythromycin 1 (0.1%) 1 (0.2%) 1 (1%)
Antifungal agent 17 (2%) 13 (2%) 14 (8%)
Imipenem 1 (0.1%) 0 (0%) 0 (0%)
Piperacillin 0 (0%) 7 (1%) 2 (1%)
Ticarcillin 5 (0.6%) 10 (2%) 4 (2%)
Other 13 (2%) 19 (4%) 7 (4%)
Abbreviation: PD, peritoneal dialysis.
Results represent the number of episodes treated with antibiotic (% of total treated
with the first-, second-, or third-line regimen). Note that values within each column
add to more than 100% because of the use of combination antimicrobial regimens.
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hemodialysis transfer (OR 2.85, 95% CI 1.88–4.33). Relapse
of NPGN peritonitis was less likely associated with poly-
microbial peritonitis (OR 0.16, 95% CI 0.53–0.46), although
this likely reflected the competing risks, as polymicrobial
peritonitis was also associated with catheter removal and
permanent hemodialysis transfer. As the number of deaths
was only 23 in the NPGN peritonitis cohort, multivariate
analysis of the predictors of death was not possible.
Increasing age was predictive of hospitalization for NPGN
peritonitis (youngest tertile reference; middle tertile OR 2.10,
95% CI 0.99–4.39; oldest tertile OR 3.15, 95% CI 1.48–6.70).
Patients with renovascular disease were less likely to undergo
permanent hemodialysis transfer (OR 0.49, 95% CI
0.26–0.93): this may relate to a bias towards attempting to
avoid long-term hemodialysis in this group, which generally
have widespread vascular disease.
DISCUSSION
The present study, involving 837 cases of PD-associated
NPGN peritonitis across 66 different PD centers, represents
the largest examination to date of the frequency, predictors,
treatment, and clinical outcomes of this important condition.
NPGN peritonitis accounted for 23% of all peritonitis
episodes and was polymicrobial in 25% of cases. Underlying
bowel perforation was uncommon (1.1%) but was signifi-
cantly more likely in polymicrobial NPGN peritonitis (2.4 vs
0.6%). The significant independent predictors of NPGN
peritonitis were older age and absence of diabetic nephro-
pathy. Despite treatment with a single antimicrobial agent in
the majority of cases for a relatively short median duration of
2 weeks, cure was achieved in 59% of them. Compared with
other organisms, NPGN peritonitis was associated with
significantly higher risks of hospitalization, catheter removal,
permanent hemodialysis transfer, and death. Polymicrobial
NPGN peritonitis was a potent predictor of catheter removal,
and permanent hemodialysis transfer.
Although the predictors of NPGN peritonitis have not
been previously examined and reported, the association of
this condition with older age in our study most likely
represents the frequent occurrence of underlying gastro-
intestinal pathology, such as diverticular disease, in the
elderly. Interestingly, the presence of diabetic nephropathy
was associated with a reduced risk of development of NPGN
peritonitis. The reason for this finding is unexplained,
although it could reflect competing risks, as we have
previously shown that patients with diabetic nephropathy
are more prone to Gram-positive peritonitis, particularly due
to S. aureus.11
The results of our study are broadly comparable to those
of Szeto et al.,3 who examined 210 consecutive cases of
Enterobacteriaceae PD-associated peritonitis at a single Hong
Kong center from 1995 to 2004. Overall cure was achieved
with antibiotics alone in 58% of the episodes (cf. 59% in our
study), although the relapse rates (36 vs 11%) and death rates
(10 vs 4%) were both considerably higher than found in our
study. Part of the apparent disparity in results could be
explained by the predominant (480%) use of PD as a renal
replacement therapy in Hong Kong, whereby hemodialysis
transfer occurred as a last resort, such that patients were
‘switched to hemodialysis only when they have ultrafiltration
failure or peritoneal sclerosis’.3 This makes it probable that
the high relapse rate could have in part reflected an attempt
to prioritize the technique survival over cure of peritonitis
episode. Consistent with this notion, Szeto et al.3 reported
markedly lower rates of catheter removal (8 vs 31%) and
permanent hemodialysis transfer (1.4 vs 26%) than in our
study. An alternative possibility is that a higher proportion of
episodes in the study by Szeto et al. were due to more
resistant species. This is supported by the fact that Szeto et al.
observed an increase in antibiotic resistance in isolated
Enterobacteriaceae over time, an increase in the risk of adverse
outcomes with prior antibiotic therapy, and an increase in
the risk of relapse with single vs dual antibiotic therapy.
Table 3 | Treatment characteristics and clinical outcomes
of PD-associated peritonitis due to non-Pseudomonas
Gram-negative or other organisms in Australia, 2003–2006
Outcome
Non-
Pseudomonas
Gram-negative
peritonitis
(n=837
episodes)
Other
organism
peritonitis
(n=2757
episodes) P value
Treatment
Change to second
antibiotic regimen
539 (64%) 1471 (53%) o0.001
Time to second
antibiotic regimen
3 (1–5) 3 (2–5) 0.06
Change to third
antibiotic regimen
173 (15%) 324 (12%) o0.001
Time to third
antibiotic regimen
6 (4–9) 7 (4–10) 0.12
Total antibiotic
treatment duration
14 (10–21) 14 (8–19) o0.001
Relapse 91 (11%) 411 (15%) 0.003
Hospitalization
Number (%) 679 (81%) 1825 (66%) o0.001
Duration (days) 7 (4–14) 6 (3–11) o0.001
Catheter removal
Number (%) 275 (31%) 518 (19%) o0.001
Time to occurrence
(days)
6 (3–10) 6 (3–15) 0.12
Temporary hemodialysis
Number (%) 34 (4%) 118 (4%) 0.8
Time to occurrence
(days)
6 (2.5–9.5) 6.5 (3–13) 0.3
Duration (days) 64 (24–88.5) 68.5 (22.5–104.75) 0.4
Permanent hemodialysis
Number (%) 219 (26%) 416 (15%) o0.001
Time to occurrence 7 (4–11) 7 (4–12) 0.3
Death
Number (%) 35 (4%) 47 (2%) o0.001
Time to death 11.5 (2–19) 12 (5–25) 0.4
Abbreviation: PD, peritoneal dialysis.
Results are expressed as number (%) or median days (interquartile range).
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Our results are also in keeping with those of Bunke et al.7
who reported similar rates of cure (58.8%), catheter removal
(30%), and death (3.7%) following 136 episodes of NPGN
PD-related peritonitis from a population of 1930 patients
over a period of 1 year. Moreover, the predominant causative
organisms were almost identical to those in our study and
other case series:2,3 E. coli, Klebsiella species, Enterobacter
species, and Serratia species, in descending order of frequency.
The poorer outcomes associated with NPGN peritonitis and
the identities of recovered organisms suggest the presence of
underlying bowel pathology in a large proportion of affected
patients. In keeping with this possibility, we observed that
NPGN peritonitis was frequently polymicrobial (25% of
cases) and was more common with increasing age.
When a single NPGN organism is identified by micro-
scopy or culture in patients with PD-associated peritonitis,
the ISPD guidelines recommend antibiotic therapy with a
single agent based on sensitivities, safety, and convenience for
a period of 3 weeks, regardless of whether or not the catheter
is removed.9 However, antibiotic treatment duration was not
related to likelihood of cure in the present study. Moreover,
the cure rate achieved with a median treatment period of
2 weeks in our study was comparable to that achieved in
the studies by Bunke et al.7 (mean treatmento2 weeks) and
Szeto et al.3 (treatment for 14–21 days). Based on the results
of our study, reasonable cure rates can be achieved for single-
organism NPGN peritonitis with single antimicrobial agents
(most commonly aminoglycoside or quinolone) based on
sensitivities for a period of 2 weeks.
Szeto et al.3 further reported that recent antibiotic therapy
was associated with marginally lower complete cure rates
(49.3 vs 62.8%), although this was not found in our study.
These results may be potentially explained by the relatively
liberal prescription of antibiotics in the primary care setting
in Hong Kong, as noted by Szeto et al.,3 with the consequent
development of antimicrobial resistance. In contrast, the
main determinant of poorer peritonitis outcomes in the
current study was recovery of multiple organisms, possibly
reflecting the presence of underlying significant bowel
pathology.9 While early reports described polymicrobial
peritonitis resulting from complications of catheter place-
ment or bowel perforation,12 later reports found polymicro-
bial peritonitis to be associated with a low incidence of
catastrophic surgical pathology (2.8–9%).13–17 In the present
study, underlying bowel perforation requiring surgical
intervention was reported in only a small proportion
(1.1%) of NPGN peritonitis episodes. Surgical bowel
pathology was significantly more common in NPGN
peritonitis than in other forms of peritonitis and was
significantly more common in polymicrobial than in
Table 4 | Treatment characteristics and clinical outcomes of PD-associated peritonitis due to NPGN organisms or other
organisms (non-NPGN) in single-organism and polymicrobial infections in Australia, 2003–2006
Single-organism peritonitis Polymicrobial peritonitis
Outcome NPGN (n=626) Non-NPGN (n=2609) P value NPGN (n=211) Non-NPGN (n=148) P value
Treatment
Change to second antibiotic regimen 242 (39%) 1365 (52%) o0.001 155 (73%) 106 (72%) 0.8
Time to second antibiotic regimen 2 (1–5) 3 (2–5) 0.12 3 (1–5) 3 (2–6) 0.08
Change to third antibiotic regimen 101 (16%) 293 (11%) o0.001 72 (34%) 31 (21%) 0.009
Time to third antibiotic regimen 6 (3.5–9) 7 (4–10) 0.02 6 (4–13) 6 (5–11) 0.7
Total antibiotic treatment duration 14 (9–20) 14 (8–19) 0.2 16 (11–23) 14 (7.75–21) 0.06
Relapse 81 (13%) 386 (15%) 0.2 10 (5%) 25 (17%) o0.001
Hospitalization
Number (%) 498 (80%) 1709 (66%) o0.001 181 (86%) 116 (78%) 0.07
Duration (days) 6 (3–11) 5 (3–11) 0.10 10 (5–20.5) 7 (3–15.5) 0.005
Catheter removal
Number (%) 152 (24%) 468 (18%) o0.001 105 (50%) 50 (34%) 0.003
Time to occurrence (days) 6 (3–10) 6 (3–14) 0.4 6 (4–10) 10 (5–21) 0.003
Temporary hemodialysis
Number (%) 23 (4%) 110 (4%) 0.5 11 (5%) 8 (5%) 0.9
Time to occurrence (days) 5.5 (2–10.25) 7 (3–12.75) 0.3 6 (4–7) 4.5 (1.5–21.25) 0.9
Duration (days) 54 (25.5–79.75) 68.5 (22.5–104) 0.3 74 (17–118) 85 (31.5–144) 0.6
Permanent hemodialysis
Number (%) 129 (21%) 368 (14%) o0.001 90 (43%) 48 (32%) 0.05
Time to occurrence 7 (4–10) 7 (4–13.75) 0.5 6 (4–11.5) 10 (6–18) 0.01
Death
Number (%) 23 (4%) 45 (2%) 0.002 12 (6%) 2 (1%) 0.04
Time to death 8 (1–15.5) 12 (5–24) 0.2 15.5 (5.5–26) 35 (3–158.5) 0.5
Abbreviations: NPGN, non-Pseudomonas Gram-negative; PD, peritoneal dialysis.
Results are expressed as number (%) or median days (interquartile range).
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single-organism NPGN peritonitis (2.4 vs 0.6%, Po0.05,
OR 3.77, 95% CI 1.004–14.2). However, the high proportion
of polymicrobial NPGN peritonitis in our study and in that
of Szeto et al.17 suggests that the bowel may still be a common
source. In cases of isolation of multiple enteric organisms, the
ISPD guidelines recommend surgical evaluation, considera-
tion of catheter removal, and treatment with metronidazole
in combination with ampicillin and ceftazidime or an
aminoglycoside. These recommendations are supported by
the findings in our study, whereby polymicrobial peritonitis
involving at least one NPGN organism was associated with
greatly increased risks of catheter removal (50%), permanent
hemodialysis transfer (43%), and death (6%). Our results
suggest that polymicrobial NPGN peritonitis often warrants
multiple antimicrobial agents and surgical evaluation.
In cases of refractory NPGN peritonitis, the ISPD
guidelines recommend removal of the catheter within 5 days
to protect the peritoneal membrane for future use.9 However,
removal of the catheter within the first 5 days of peritonitis
onset as opposed to later did not significantly affect the
probabilities of either permanent hemodialysis transfer or
death in our study, regardless of whether single-organism or
polymicrobial peritonitis episodes were considered. This
finding was not likely to result from lack of statistical power,
as the number of catheters removed during the study period
(n¼ 793) was large.
Although severe peritonitis has been identified in some
reports as a risk factor for encapsulating peritoneal sclerosis
(EPS),18–20 no EPS cases were reported following NPGN
peritonitis episodes in the present study. These results are in
keeping with a recently published ANZDATA Registry study,
which found that EPS was predicted by age and PD duration,
but not by peritonitis rate or type.21
The strengths of this study included its very large sample
size and inclusiveness. We included all patients receiving PD
in Australia across 66 centers during the study period, such
that a variety of centers with varying approaches to the
treatment of peritonitis were included. This greatly enhanced
the external validity of our findings. These strengths should
be balanced against the study’s limitations, which included
limited depth of data collection. ANZDATA does not collect
important information, such as the presence of concomitant
exit site and tunnel infections, patient compliance, individual
unit management protocols, laboratory values (such as
C-reactive protein and dialysate white cell counts), severity
of comorbidities, antimicrobial susceptibilities of recovered
organisms, antibiotic dosages, or routes of antibiotic
administration. Even though we adjusted for a large number
of patient characteristics, the possibility of residual con-
founding could not be excluded. In common with other
Registries, ANZDATA is a voluntary Registry and there is no
external audit of data accuracy, including the diagnosis of
peritonitis. Consequently, the possibility of coding/classifica-
tion bias cannot be excluded.
In conclusion, NPGN peritonitis is a frequent, serious
complication of PD, which is associated with significant risks
of hospitalization, catheter removal, permanent hemodialysis
transfer, and death. Cure with antibiotics alone is achievable
in only 60% of cases and is much less likely when multiple
organisms are isolated.
MATERIALS AND METHODS
Study population
The study included all Australian adult patients from the ANZDATA
Registry who were receiving PD between 1 October 2003 (when
detailed peritonitis data began to be collected) and 31 December
2006. The data collected included demographic data, cause of
primary renal disease, comorbidities at the start of dialysis
(coronary artery disease, peripheral vascular disease, cerebrovascular
disease, chronic lung disease, diabetes, hypertension, and smoking
status), BMI, late referral (defined as commencement of dialysis
within 3 months of referral to a nephrologists), microbiology of
peritonitis episodes (up to three organisms for polymicrobial
episodes), and the initial and subsequent antibiotic treatment
regimens. Diagnosis of peritonitis was made based on a PD effluent
white cell count 4100/ml, with 450% polymorphonuclear
leukocytes. In cases of polymicrobial peritonitis, NPGN peritonitis
was recorded if an NPGN species was at least one of the isolated
organisms. Center size was categorized according to quartiles of the
numbers of patients cared for by individual units over the duration
of the study: small (o11 patients over the study period),
small–medium (11–38 patients), medium–large (39–98 patients),
and large (499 patients).
The outcomes examined were peritonitis relapse, repeat
peritonitis, peritonitis-associated hospitalization, catheter removal,
temporary or permanent transfer to hemodialysis, and patient
death. Peritonitis relapse was defined as an episode of peritonitis
occurring within 4 weeks of the last antibiotic dose (or within
5 weeks if intermittent vancomycin was used) for peritonitis due to
the same organism. A relapse was not counted as a separate episode
of peritonitis. Repeat peritonitis was defined as an episode of
peritonitis occurring more than 4 weeks after the last antibiotic dose
(or more than 5 weeks if intermittent vancomycin was used) for
peritonitis due to the same organism. A peritonitis episode was
considered ‘cured’ by antibiotics alone if the patient was symptom
free, the PD effluent was clear, and the episode was not complicated
by relapse, catheter removal, or death. Peritonitis-related death was
recorded if the patient’s death was directly attributable to peritonitis
in the clinical opinion of the treating nephrologist.
Statistical analysis
Results were expressed as frequencies and percentages for categorical
variables, mean ± s.d. for continuous variables, and median and
interquartile range for non-parametric data. Differences between
two groups of patients were analyzed by w2 test for categorical data,
unpaired t-test for continuous parametric data, and Mann–Whitney
test for continuous non-parametric data. The independent pre-
dictors of NPGN peritonitis were determined by multivariate,
multilevel mixed-effects Poisson regression analysis. In order to
account for the structure of the data, this multilevel hierarchical
model was created with a random effect for state of residence,
treating unit, and individual patient.22 Predictors of peritonitis
outcomes were determined by multivariate, multilevel mixed-effects
logistic regression using stepwise backward elimination. First-order
interaction terms between the significant covariates were examined
for all analyses. Data were analyzed using the SPSS software package
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for Windows release 12.0 (SPSS Inc., North Sydney, New South
Wales, Australia) and Stata/s.e. 10.0 (College Station, TX, USA).
P values o0.05 were considered statistically significant.
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